Literature DB >> 27621859

A lot to a little or a little to a lot-which dose-volume relationship ensures the best clinical outcome in the high dose radiation therapy of thoracic tumors? A prospective approach.

Christina Schröder1, Rita Engenhart-Cabillic2, Hilke Vorwerk2, Michael Schmidt3, Winfried Huhnt3, Eyck Blank3, Dietrich Sidow3, André Buchali3.   

Abstract

BACKGROUND: The purpose of this prospective randomized trial is to determine which constellation of dose and corresponding volume of the lung tissue-either a lot to a little or a little to a lot-should be preferred to ensure the best possible outcome for patients with thoracic carcinomas.
METHODS: From Apr 2012 to Oct 2015, 81 patients with NSCLC, SCLC or esophageal carcinoma were randomized and treated with either a 4-field-IMRT or a VMAT technique with or without additional chemotherapy. Data regarding clinical outcome, pulmonary function tests (PFT) and quality of life (QoL) was collected before RT, 6 weeks, 12 weeks and 6 months after treatment, QoL data additionally 1 year post RT. Follow up CTs were done 12 weeks and 6 months after RT.
RESULTS: There is no significant difference regarding the local (P=0.954) and distant (P=0.206) outcome, side effects (all P>0.05) or survival (P=0.633) at any follow-up appointment. The comparison of the PFT shows a statistically significant difference for the DLCO 6 weeks post RT (P=0.028). All other parameters do not differ significantly at any follow up appointment. Regarding the QoL there is no statistically significant difference at any follow up appointment (P>0.1). There is a statistically significant difference between the mean density of the lung parenchyma at 12 weeks (P<0.0005) and 6 months post RT (P<0.0005).
CONCLUSIONS: Since there is no significant and relevant difference between both treatment arms regarding PFT, clinical outcome and QoL it does not seem to relevant how the DVH is shaped exactly as long as established dose constraints for the organs at risk are respected. As to whether the difference between the CT density changes is clinically relevant further analysis is needed.

Entities:  

Keywords:  Lung neoplasms; intensity modulated radiotherapy (IMRT); quality of life (QoL); radiation pneumonitis (RP); respiratory function tests

Year:  2016        PMID: 27621859      PMCID: PMC4999719          DOI: 10.21037/jtd.2016.07.92

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  28 in total

1.  Pulmonary function following high-dose radiotherapy of non-small-cell lung cancer.

Authors:  Katrien De Jaeger; Yvette Seppenwoolde; Liesbeth J Boersma; Sara H Muller; Paul Baas; José S A Belderbos; Joos V Lebesque
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-04-01       Impact factor: 7.038

2.  Health related quality of life in locally advanced NSCLC treated with high dose radiotherapy and concurrent chemotherapy or cetuximab--pooled results from two prospective clinical trials.

Authors:  Andreas Hallqvist; Bengt Bergman; Jan Nyman
Journal:  Radiother Oncol       Date:  2012-06-23       Impact factor: 6.280

Review 3.  Lung toxicity following chest irradiation in patients with lung cancer.

Authors:  Raymond P Abratt; Graeme W Morgan
Journal:  Lung Cancer       Date:  2002-02       Impact factor: 5.705

4.  Acute radiation pneumonitis after conformational radiotherapy for nonsmall cell lung cancer: clinical, dosimetric, and associated-treatment risk factors.

Authors:  Etienne Giroux Leprieur; Diego Fernandez; Gilles Chatellier; Sylvain Klotz; Philippe Giraud; Catherine Durdux
Journal:  J Cancer Res Ther       Date:  2013 Jul-Sep       Impact factor: 1.805

5.  Changes in pulmonary function after three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, or proton beam therapy for non-small-cell lung cancer.

Authors:  Jose L Lopez Guerra; Daniel R Gomez; Yan Zhuang; Lawrence B Levy; George Eapen; Hongmei Liu; Radhe Mohan; Ritsuko Komaki; James D Cox; Zhongxing Liao
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-03-13       Impact factor: 7.038

6.  Lack of a dose-effect relationship for pulmonary function changes after stereotactic body radiation therapy for early-stage non-small cell lung cancer.

Authors:  Matthias Guckenberger; Rainer J Klement; Larry L Kestin; Andrew J Hope; Jose Belderbos; Maria Werner-Wasik; Di Yan; Jan-Jakob Sonke; Jean-Pierre Bissonnette; Ying Xiao; Inga S Grills
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-11-12       Impact factor: 7.038

7.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.

Authors:  N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes
Journal:  J Natl Cancer Inst       Date:  1993-03-03       Impact factor: 13.506

8.  Effects of radiotherapy and chemotherapy on lung function in patients with non-small-cell lung cancer.

Authors:  Ramesh Gopal; George Starkschall; Susan L Tucker; James D Cox; Zhongxing Liao; Michael Hanus; Jason F Kelly; Craig W Stevens; Ritsuko Komaki
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-05-01       Impact factor: 7.038

9.  Long-term changes in pulmonary function after incidental lung irradiation for breast cancer: a prospective study with 7-year follow-up.

Authors:  Javier Jaén; Gonzalo Vázquez; Enrique Alonso; Maria D De Las Peñas; Laura Díaz; Manuel De Las Heras; José F Pérez-Regadera
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-08-25       Impact factor: 7.038

10.  No clinically significant changes in pulmonary function following stereotactic body radiation therapy for early- stage peripheral non-small cell lung cancer: an analysis of RTOG 0236.

Authors:  Sinisa Stanic; Rebecca Paulus; Robert D Timmerman; Jeff M Michalski; Robert B Barriger; Andrea Bezjak; Gregory M M Videtic; Jeffrey Bradley
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-04-01       Impact factor: 7.038

View more
  2 in total

1.  Pulmonary function changes following helical tomotherapy in patients with inoperable, locally advanced non-small cell lung cancer.

Authors:  K Vekens; S Verbanck; C Collen; G Storme; K Barbé; M De Ridder; E Vanderhelst
Journal:  Strahlenther Onkol       Date:  2019-07-12       Impact factor: 3.621

2.  Radiotherapy-Related Dose and Irradiated Volume Effects on Breast Cancer Risk Among Hodgkin Lymphoma Survivors.

Authors:  Sander Roberti; Flora E van Leeuwen; Cécile M Ronckers; Inge M Krul; Florent de Vathaire; Cristina Veres; Ibrahima Diallo; Cécile P M Janus; Berthe M P Aleman; Nicola S Russell; Michael Hauptmann
Journal:  J Natl Cancer Inst       Date:  2022-09-09       Impact factor: 11.816

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.